Factor V Leiden, Prothrombin Gene G20210A Variant, and Methylenetetrahydrofolate Reductase C677T Genotype in Young Adults With Ischemic Stroke

Ischemic stroke in young adults is a well-known disease, but despite extensive clinical and laboratory investigations, its etiology remains unclear in approximately half of the cases. We examined the prevalence of factor V Leiden, the prothrombin G20210A genotype, and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in 100 patients (51 males and 49 females) who survived an ischemic stroke without a cardiac embolic source at an age ≤45 years, and in 238 healthy control subjects from the same geographic area. The patients were selected for study only if the diagnosis of stroke was documented by computed tomography scan or nuclear magnetic resonance (NMR) of the brain, or both. Heterozygosity for the FV Leiden mutation was found in 3 patients (3.0%) and in 10 control subjects (4.2%). Two patients (2.0%) and five control subjects (2.1%) were heterozygous for the prothrombin G20210A mutation. The frequencies of the MTHFR 677TT, CT, and CC genotypes in the patient group were 12%, 37%, and 51%, respectively, and were not significantly different from those in control subjects (11%, 40%, and 49%, respectively). In conclusion, our results indicate that FV Leiden mutation, prothrombin G20210A genotype, and homozygosity for the C677T mutation in the MTHFR gene are not associated with an increased risk for ischemic stroke in young adults.

[1]  R. Bertina.  Molecular Risk Factors for Thrombosis , 1999, Thrombosis and Haemostasis.

[2]  M. Margaglione,et al.  Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[3]  D. Mari,et al.  Prothrombin Gene Mutation (G20210A) in Healthy Centenarians , 1999, Thrombosis and Haemostasis.

[4]  E. Chalmers,et al.  Factor V Leiden, Prothrombin 20210 G → A and the MTHFR C677T Mutations in Childhood Stroke , 1999, Thrombosis and Haemostasis.

[5]  A J Marian,et al.  Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. , 1999, Stroke.

[6]  P. Ridker,et al.  G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. , 1999, Circulation.

[7]  L. Deecke,et al.  C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. , 1999, Thrombosis research.

[8]  D. Wilcken,et al.  Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. , 1998, Circulation.

[9]  W. Kreuz,et al.  Thrombophilic disorders in children with cerebral infarction , 1998, The Lancet.

[10]  F. Paky,et al.  Factor V Leiden and Prothrombin Gene G 20210 A Variant in Children with Ischemic Stroke , 1998, Thrombosis and Haemostasis.

[11]  S. Kristensen,et al.  Factor V Leiden and Venous Thrombosis in Danish Centenarians , 1998, Thrombosis and Haemostasis.

[12]  T. Baglin,et al.  Effect of the MTHFRC677T variant on risk of venous thromboembolism: interaction with factor V Leiden and prothrombin (F2G20210A) mutations , 1998, British journal of haematology.

[13]  C. Kessler,et al.  Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients , 1998, Journal of Neurology.

[14]  YoshioYazaki,et al.  Methylenetetrahydrofolate Reductase Gene Polymorphism and Ischemic Stroke in Japanese , 1998 .

[15]  P. Chiusolo,et al.  Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. , 1998, Blood.

[16]  P. Reitsma,et al.  Geographic Distribution of the 20210 G to A Prothrombin Variant , 1998, Thrombosis and Haemostasis.

[17]  M. Kaps,et al.  The Mutation C677 → T in the Methylene Tetrahydrofolate Reductase Gene and Stroke , 1998, Thrombosis and Haemostasis.

[18]  M. Zago,et al.  Analysis of the 677 C→T Mutation of the Methylenetetrahydrofolate Reductase Gene in Different Ethnic Groups , 1998, Thrombosis and Haemostasis.

[19]  E. Antón,et al.  [Stroke in young adults]. , 1998, Anales de medicina interna.

[20]  O. Thorarensen,et al.  Factor V Leiden mutation: An unrecognized cause of hemiplegic cerebral palsy, neonatal stroke, and placental thrombosis , 1997, Annals of neurology.

[21]  F. Costa,et al.  The Mutation Ala677→Val in the Methylene Tetrahydrofolate Reductase Gene: A Risk Factor for Arterial Disease and Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[22]  S. Lopaciuk,et al.  Prevalence of factor V Leiden mutation in various populations , 1997, Genetic epidemiology.

[23]  L. Taylor,et al.  Homocysteinemia as a risk factor for atherosclerosis: a review. , 1997, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[24]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[25]  U. Nowak‐Göttl,et al.  Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[26]  I. Martinelli,et al.  Arg506Gln factor V mutation and cerebral ischemia in the young. , 1996, Stroke.

[27]  F. Chollet,et al.  Frequency of resistance to activated protein C due to factor V mutation in young patients with ischemic stroke. , 1996, Stroke.

[28]  N. Dzimiri,et al.  World distribution of factor V Leiden , 1996, The Lancet.

[29]  R. Kekomäki,et al.  Physiological anticoagulants and activated protein C resistance in childhood stroke , 1996, Acta paediatrica.

[30]  J. Cookson,et al.  Activated protein C resistance in childhood stroke , 1996, The Lancet.

[31]  R. Press,et al.  Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. , 1996, Stroke.

[32]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[33]  J. Barrett,et al.  Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[35]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[36]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[37]  H. R. Martinez,et al.  Ischemic Stroke Due to Deficiency of Coagulation Inhibitors: Report of 10 Young Adults , 1993, Stroke.

[38]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[39]  Ruth Bonita,et al.  Epidemiology of stroke , 1992, The Lancet.

[40]  K. Matsushita,et al.  Cerebral Infarction Associated With Protein C Deficiency , 1992, Stroke.

[41]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.